Clinical Trial Update: BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating BYL719 (alpelisib) with letrozole in post-menopausal women with hormone receptor-positive metastatic breast cancer; trial stat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer
• Invasive Ductal Carcinoma
• Progesterone Receptor-positive Breast Cancer

Drugs mentioned

• BYL719 (alpelisib)
• Letrozole (letrozole)

Snippet

Sponsor: Vanderbilt-Ingram Cancer Center | Conditions: Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING